Overview

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment

Status:
Not yet recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

The study aims to evaluate the efficacy and safety of PD-L1 antibody combined with the CTLA-4 antibody in patients with advanced ICC who progressed after standard treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Treatments:

Antibodies
Immunoglobulins